Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 9 | 2013 | 362 | 0.800 |
Why?
|
| Daptomycin | 6 | 2013 | 10 | 0.740 |
Why?
|
| Gram-Positive Bacterial Infections | 4 | 2013 | 54 | 0.610 |
Why?
|
| Enterococcus | 4 | 2013 | 55 | 0.460 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2011 | 11 | 0.410 |
Why?
|
| Bacteremia | 2 | 2010 | 98 | 0.370 |
Why?
|
| Vancomycin Resistance | 2 | 2010 | 29 | 0.340 |
Why?
|
| Oxazolidinones | 1 | 2010 | 2 | 0.330 |
Why?
|
| Acetamides | 1 | 2010 | 2 | 0.330 |
Why?
|
| Gout Suppressants | 1 | 2010 | 1 | 0.320 |
Why?
|
| Urate Oxidase | 1 | 2010 | 1 | 0.320 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2010 | 1 | 0.320 |
Why?
|
| Hyperuricemia | 1 | 2010 | 2 | 0.320 |
Why?
|
| Drug Dosage Calculations | 1 | 2010 | 6 | 0.320 |
Why?
|
| Body Weight | 1 | 2010 | 129 | 0.310 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 63 | 0.300 |
Why?
|
| Pharmacists | 3 | 2011 | 16 | 0.240 |
Why?
|
| HIV Infections | 1 | 2009 | 431 | 0.230 |
Why?
|
| beta-Lactams | 3 | 2011 | 9 | 0.230 |
Why?
|
| Staphylococcus aureus | 3 | 2015 | 72 | 0.200 |
Why?
|
| Retrospective Studies | 10 | 2015 | 2994 | 0.190 |
Why?
|
| Staphylococcal Infections | 3 | 2015 | 156 | 0.170 |
Why?
|
| Medication Errors | 2 | 2011 | 12 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2015 | 2941 | 0.170 |
Why?
|
| Antifungal Agents | 2 | 2011 | 36 | 0.160 |
Why?
|
| Shock, Septic | 2 | 2010 | 25 | 0.160 |
Why?
|
| Humans | 20 | 2015 | 22958 | 0.150 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2008 | 20 | 0.130 |
Why?
|
| Middle Aged | 11 | 2015 | 7911 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 15 | 0.120 |
Why?
|
| Adult | 9 | 2015 | 6927 | 0.120 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2015 | 17 | 0.120 |
Why?
|
| Anesthetics | 1 | 2015 | 20 | 0.120 |
Why?
|
| Cefazolin | 1 | 2015 | 3 | 0.120 |
Why?
|
| Oxacillin | 1 | 2015 | 2 | 0.120 |
Why?
|
| Methicillin | 1 | 2015 | 6 | 0.120 |
Why?
|
| Child Development | 1 | 2015 | 67 | 0.110 |
Why?
|
| Aged | 9 | 2015 | 7448 | 0.110 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2015 | 172 | 0.110 |
Why?
|
| Male | 11 | 2015 | 12466 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2011 | 52 | 0.100 |
Why?
|
| Female | 11 | 2015 | 12958 | 0.100 |
Why?
|
| Enterococcus faecalis | 1 | 2013 | 5 | 0.100 |
Why?
|
| Endocarditis | 1 | 2013 | 10 | 0.100 |
Why?
|
| Enterococcus faecium | 1 | 2013 | 12 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 210 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2010 | 286 | 0.100 |
Why?
|
| Medication Reconciliation | 1 | 2011 | 1 | 0.090 |
Why?
|
| Carbapenems | 1 | 2011 | 45 | 0.090 |
Why?
|
| Amphotericin B | 1 | 2011 | 5 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2011 | 5 | 0.090 |
Why?
|
| beta-Lactam Resistance | 2 | 2008 | 14 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 6 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 13 | 0.090 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 25 | 0.080 |
Why?
|
| Linezolid | 1 | 2010 | 4 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2015 | 1417 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 60 | 0.080 |
Why?
|
| Fluid Therapy | 1 | 2010 | 19 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2013 | 83 | 0.080 |
Why?
|
| Uric Acid | 1 | 2010 | 7 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 17 | 0.080 |
Why?
|
| Drug Costs | 1 | 2010 | 8 | 0.080 |
Why?
|
| Cost Savings | 1 | 2010 | 29 | 0.080 |
Why?
|
| Medication Therapy Management | 1 | 2009 | 3 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2010 | 40 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 107 | 0.080 |
Why?
|
| Time Factors | 5 | 2011 | 1262 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2010 | 66 | 0.080 |
Why?
|
| Candidiasis | 1 | 2009 | 23 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2011 | 3728 | 0.080 |
Why?
|
| Nurses | 1 | 2009 | 41 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 235 | 0.070 |
Why?
|
| Prognosis | 1 | 2010 | 730 | 0.070 |
Why?
|
| Professional Competence | 1 | 2008 | 34 | 0.070 |
Why?
|
| Risk Factors | 2 | 2010 | 1971 | 0.070 |
Why?
|
| Biomarkers | 1 | 2010 | 476 | 0.070 |
Why?
|
| Bacterial Infections | 1 | 2007 | 47 | 0.070 |
Why?
|
| Chicago | 1 | 2010 | 813 | 0.070 |
Why?
|
| Critical Care | 1 | 2008 | 97 | 0.060 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 11 | 0.060 |
Why?
|
| Bone Diseases | 1 | 2005 | 19 | 0.060 |
Why?
|
| Young Adult | 1 | 2010 | 1651 | 0.060 |
Why?
|
| Joint Diseases | 1 | 2005 | 87 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 153 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 315 | 0.040 |
Why?
|
| Hospital Mortality | 2 | 2010 | 129 | 0.040 |
Why?
|
| Hospitalization | 2 | 2011 | 286 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2011 | 1493 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2015 | 537 | 0.030 |
Why?
|
| Blood | 1 | 2013 | 17 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2013 | 19 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 228 | 0.020 |
Why?
|
| Pseudomonas | 1 | 2011 | 2 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 35 | 0.020 |
Why?
|
| Continuity of Patient Care | 1 | 2011 | 17 | 0.020 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 32 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 40 | 0.020 |
Why?
|
| Bilirubin | 1 | 2011 | 10 | 0.020 |
Why?
|
| Liposomes | 1 | 2011 | 13 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 41 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 59 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 190 | 0.020 |
Why?
|
| Resuscitation | 1 | 2010 | 10 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 52 | 0.020 |
Why?
|
| Health Services Research | 1 | 2010 | 29 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 137 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 948 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 638 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 624 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 318 | 0.020 |
Why?
|
| Inpatients | 1 | 2009 | 113 | 0.020 |
Why?
|
| Knowledge | 1 | 2008 | 12 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2010 | 234 | 0.020 |
Why?
|
| Problem Solving | 1 | 2008 | 38 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 801 | 0.020 |
Why?
|
| Vancomycin | 1 | 2008 | 51 | 0.020 |
Why?
|
| Cross Infection | 1 | 2010 | 295 | 0.020 |
Why?
|
| Communication | 1 | 2008 | 96 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 120 | 0.020 |
Why?
|
| beta-Lactamases | 1 | 2008 | 94 | 0.020 |
Why?
|
| Decision Making | 1 | 2008 | 176 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 243 | 0.020 |
Why?
|
| United States | 1 | 2011 | 1765 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 3311 | 0.010 |
Why?
|